China HeadAche DIsorders RegiStry

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Duration - Up to 10 years

Participants with different types of primary headache are followed up according to their headache subtype. For Medicine Overuse Headache and New Daily Persistent Headache, participants have monthly visits for the first 18 months, a visit at 24 months, then annual visits thereafter. For Chronic Migraine and Episodic Migraine, participants have visits at 1, 2, 3, 6, 9, 12, 18, and 24 months, then annual visits. For other primary headaches, participants have visits at 3, 6, and 9 months.

Monthly visits for 18 months, then visits at 24 months and annually thereafter depending on headache type

Duration - 12 weeks

Participants prescribed Yangxue Qingnao Granules/Pills in routine clinical practice are observed over a 12-week period. Treatment initiation, dosing, frequency, and duration are determined by the treating physician and patient. Participants are followed with outcome assessments including relief of headache episodes and symptom measures at weeks 4, 8, and 12.

Visits at baseline, and weeks 4, 8, and 12

Duration - 12 weeks with possible additional follow-up

Participants receiving eptinezumab or erenumab for migraine prophylaxis in routine clinical practice are observed. Treatment decisions are made by the treating physician and patient. Outcome assessments are captured approximately every 4 weeks during a 12-week observation window, with additional follow-up when available.

Visits approximately every 4 weeks during 12 weeks